Clinical Trial Update: Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia [Phase 2]

View source ↗

Summary

Phase 2 study of Posoleucel (formerly ALVR105; Viralym-M) in kidney transplant patients with BK viremia has completed, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bk Virus Infection
• Bk Virus Nephropathy

Drugs mentioned

• Posoleucel (Posoleucel)

Snippet

Sponsor: AlloVir | Conditions: BK Virus Nephropathy, BK Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2024-05-16